ライフサイエンスコーパス: nicotine replacement therapy

1 CU focus mainly on the safety (mortality) of nicotine replacement therapy.

2 r, tailored and targeted materials, and free nicotine replacement therapy.

3 vices that included a behavioral program and nicotine-replacement therapy.

4 the behavioral program and full coverage of nicotine-replacement therapy.

5 coverage of both the behavioral program and nicotine-replacement therapy.

6 6%, respectively; unadjusted odds ratio with nicotine-replacement therapy, 1.26; 95% confidence inter

7 04 participants) than in the group receiving nicotine-replacement therapy (174 events among 134 parti

8 significantly lower for varenicline than for nicotine replacement therapy (2.28% compared with 3.16%)

9 64 of 655) and 31% of participants receiving nicotine-replacement therapy (203 of 655), for a differe

10 that stocked cessation medications, 96% had nicotine replacement therapy, 28% had bupropion, and 1%

11 he primary outcome, cytisine was superior to nicotine-replacement therapy among women and noninferior

12 macotherapy to behavioral therapy, including nicotine replacement therapy and bupropion, can increase

13 se trials of harm reduction options, such as nicotine replacement therapy and electronic cigarettes (

14 fficient data preclude recommendations as to nicotine replacement therapy and management of iatrogeni

15 ing the quit date, all participants received nicotine replacement therapy and their smoking behavior

16 abstinence and by pharmacotherapies such as nicotine replacement therapy and varenicline tartrate ma

17 ng men, and were higher among those who used nicotine replacement therapy and who had higher levels o

18 Use of nicotine-replacement therapies and the antidepressant bu

19 ance was low; only 7.2% of women assigned to nicotine-replacement therapy and 2.8% assigned to placeb

20 participants, 521 were randomly assigned to nicotine-replacement therapy and 529 to placebo.

21 Cigarette smoking, nicotine replacement therapy, and smokeless tobacco use

22 d to treat tobacco dependence, bupropion and nicotine replacement therapy, are effective for only a f

23 Recent research has explored the use of nicotine replacement therapy as an adjunct for enhanced

24 ontinuous abstinence was superior to that of nicotine-replacement therapy at 1 week, 2 months, and 6

25 r the 3 licensed smoking cessation therapies-nicotine replacement therapy, bupropion, and varenicline

26 ine drugs licensed to aid smoking cessation (nicotine replacement therapy, bupropion, and varenicline

27 he availability, sales, and affordability of nicotine replacement therapy, bupropion, and varenicline

28 ly important when evaluating the benefits of nicotine-replacement therapies during human pregnancies,

29 Nicotine replacement therapy effectively delivers nicoti

30 macodynamic properties of different forms of nicotine replacement therapy, empirical data are insuffi

31 e not allowed to write NHS prescriptions for nicotine-replacement therapy, even though this is the on

32 Smokers or people undergoing nicotine replacement therapy excrete approximately 10% o

33 ehavioral program and 50 percent coverage of nicotine-replacement therapy (flipped coverage), or full

34 ed a randomized, placebo-controlled study of nicotine replacement therapy for the reduction of agitat

35 positive allosteric modulator would augment nicotine replacement therapy for those with this risk va

36 1:1 ratio to receive cytisine for 25 days or nicotine-replacement therapy for 8 weeks.

37 or smoking very low nicotine cigarettes plus nicotine replacement therapy) for 30 days before their t

38 ; 95% confidence interval, 4-12) died in the nicotine replacement therapy group as compared with ten

39 but equivalent quit rates by genotype in the nicotine-replacement therapy groups.

40 Little data exist about the effectiveness of nicotine replacement therapy in adolescents, but there i

41 upport, cytisine was found to be superior to nicotine-replacement therapy in helping smokers quit smo

42 hether cytisine was at least as effective as nicotine-replacement therapy in helping smokers to quit.

43 Our study shows that nicotine replacement therapy is associated with increase

44 Nicotine replacement therapy is heavily promoted to the

45 Nicotine replacement therapy is not associated with incr

46 The most popular form of nicotine replacement therapy is the patch, and its use h

47 Nicotine-replacement therapy is effective for smoking ce

48 Use of bupropion in combination with nicotine replacement therapy may be particularly helpful

49 events in patients receiving varenicline or nicotine replacement therapy (N=35,800) and to assess re

50 In controlled clinical trials, nicotine replacement therapy (NRT) and the antidepressan

51 concentrations resulting from tobacco use or nicotine replacement therapy (NRT) are sufficient to inh

52 ng and Nicotine in Pregnancy) trial compared nicotine replacement therapy (NRT) patches with placebo

53 ple who had stopped smoking and used various nicotine replacement therapy (NRT) products.

54 examined the association between duration of nicotine replacement therapy (NRT) use and smoking cessa

55 ette use only, former smokers with long-term nicotine replacement therapy (NRT) use only, long-term d

56 to quit, but it is unclear whether combining nicotine replacement therapy (NRT) with varenicline to i

57 Smokers who use nicotine replacement therapy (NRT), bupropion, or vareni

58 e undertook large-scale distribution of free nicotine replacement therapy (NRT).

59 available data on cardiovascular risk during nicotine replacement therapy (NRT).

60 ntial clinical considerations with regard to nicotine-replacement therapy (NRT) are presented.

61 e 3 first-line smoking cessation treatments (nicotine replacement therapy [NRT], bupropion, and varen

62 s and propensity score for administration of nicotine replacement therapy on intensive care unit admi

63 of this study was to determine the impact of nicotine replacement therapy on the outcomes of critical

64 ay to aid smoking cessation is by the use of nicotine replacement therapies or partial nAChR agonists

65 Among 63 eligible RCTs involving 21 nicotine replacement therapy RCTs, 28 bupropion RCTs, an

66 coverage of both the behavioral program and nicotine-replacement therapy (reduced coverage), full co

67 es and to establish if smoking cessation and nicotine replacement therapy reverse the mechanisms invo

68 Nicotine replacement therapy (RR, 1.60 [CI, 1.53 to 1.68

69 varenicline (RR, 1.34; 95% CI, 0.66-2.66) or nicotine replacement therapy (RR, 1.95; 95% CI, 0.26-4.3

70 There was an elevated risk associated with nicotine replacement therapy that was driven predominant

71 itted to the intensive care unit may receive nicotine replacement therapy to prevent nicotine withdra

72 itted to the intensive care unit may receive nicotine replacement therapy to prevent withdrawal.

73 Nicotine replacement therapy use followed a similar patt

74 alth, smoking and treatment characteristics (nicotine replacement therapy vs. other pharmacotherapy;

75 The evidence about nicotine replacement therapies was inconclusive (RR: 1.2

76 illness and invasive mechanical ventilation, nicotine replacement therapy was independently associate

77 nt therapy on intensive care unit admission, nicotine replacement therapy was not associated with inc

78 ases, one control smoker who did not receive nicotine replacement therapy was selected based on the s

79 ne was provided by mail, free of charge, and nicotine-replacement therapy was provided through vouche

80 Those who received nicotine replacement therapy were considered as cases, a

81 d cessation and perinatal health; effects of nicotine replacement therapy were not significant.

82 ce, is a predictive biomarker of response to nicotine replacement therapy, with increased quit rates